7.7 Post-HSCT Relapse: Surveillance, Immunologic Manipulation & Treatment
Key Takeaways
- Relapse remains a leading cause of death after allogeneic HCT, and the outline lists disease relapse as a distinct element of late post-transplant management alongside subsequent malignancy and follow-up care.
- Falling donor chimerism and rising measurable residual disease can precede morphologic relapse, which is why surveillance is scheduled prospectively rather than triggered by symptoms.
- The first therapeutic lever after allogeneic HCT is usually immunologic rather than cytotoxic: withdrawing immunosuppression to restore a graft-versus-malignancy effect, at the cost of precipitating or worsening GVHD.
- Donor lymphocyte infusion augments graft-versus-malignancy but carries GVHD and marrow aplasia risk, and its dose, timing, and disease context are individualized rather than standardized.
Why Relapse Surveillance Is Scheduled, Not Triggered
Despite everything conditioning and the graft accomplish, relapse of the underlying malignancy remains one of the leading causes of death after allogeneic hematopoietic cell transplantation, and the official outline lists disease relapse as its own element of late post-transplant management. The clinical problem is that by the time relapse produces symptoms - cytopenias, fatigue, bone pain, adenopathy, a new mass - the disease burden is usually substantial and the therapeutic options have narrowed.
Surveillance therefore runs on a schedule set by the disease and the transplant platform rather than in response to how the patient feels. Three streams of evidence typically move before morphology does:
- Donor chimerism. A falling proportion of donor cells, particularly in the lineage the disease occupies, can precede relapse. Lineage-specific testing is more informative than whole-blood chimerism because a T-cell decline and a myeloid decline mean different things.
- Measurable residual disease. Flow cytometric or molecular MRD detects disease well below the morphologic threshold, and its rise is frequently the earliest actionable signal.
- Disease-specific imaging and marrow assessment, performed at protocol-defined milestones.
The nursing contribution is unglamorous and decisive: keeping the surveillance calendar from slipping. Patients feel well, live far away, and are tired of appointments, and a missed milestone marrow or chimerism draw removes exactly the lead time these tests exist to provide.
The First Lever Is Immunologic
After allogeneic transplantation the most powerful antitumor mechanism available is the donor immune system, so the first response to impending or early relapse is usually to unleash it rather than to add cytotoxic therapy.
Withdrawal of immunosuppression. Tapering or stopping calcineurin inhibitors and other agents restores donor T-cell activity against residual disease. The trade-off is explicit and unavoidable: the same donor T cells that attack the malignancy attack host tissue, so accelerated withdrawal precipitates or worsens graft-versus-host disease. Patients need to understand before the taper that a rash or diarrhea is an anticipated consequence of the strategy rather than a sign it has failed, and nursing surveillance for GVHD intensifies during and after the taper.
Donor lymphocyte infusion (DLI). Additional donor lymphocytes are given to augment the graft-versus-malignancy effect. It is most effective in diseases with slower kinetics and lower burden, which is another reason early detection matters. The two principal risks are GVHD, which may be severe, and marrow aplasia, since donor lymphocytes may attack residual host hematopoiesis. Dose, escalation schedule, timing relative to immunosuppression withdrawal, and disease context are individualized; there is no universal DLI dose to memorize. Nursing preparation includes confirming donor availability and collection scheduling, reviewing the GVHD monitoring plan, and ensuring the patient understands the intended effect and the risks being accepted.
Where Cytotoxic, Targeted and Maintenance Therapy Fit
Immunologic manipulation is not always sufficient or appropriate, and several other approaches are used alone or in combination.
| Approach | Typical role | Principal considerations |
|---|---|---|
| Maintenance therapy | Started after transplant in defined high-risk diseases to delay or prevent relapse | Adherence over months to years, cytopenias, and drug interactions with immunosuppression |
| Targeted therapy | Directed at a specific molecular lesion when one is present | Availability depends on disease biology; toxicity profiles differ substantially from chemotherapy |
| Reinduction chemotherapy | Reduces burden before an immunologic or transplant-based strategy | Toxicity in a patient with limited reserve; infection risk during renewed aplasia |
| Cellular therapy | CAR T or other immune effector approaches for eligible diseases after transplant | Eligibility, manufacturing time, and the toxicity window discussed elsewhere in this guide |
| Second transplantation | Considered in selected patients, usually with a different donor or platform | Substantially higher non-relapse mortality; requires renewed evaluation, consent, and goals discussion |
| Palliative and supportive care | Integrated at any point, not only when disease-directed options end | Symptom control, function, and goals; introducing it early preserves choice |
The Conversation That Accompanies the Diagnosis
Relapse after transplant is experienced very differently from an initial diagnosis. Patients and families have already spent months in an intensive, hopeful, exhausting process and were often told this was the definitive treatment. The news lands as the failure of something irreplaceable.
Nursing has a specific role here. Allow the news to be absorbed before layering treatment options onto it, and expect to repeat information that was said while the patient could not hear it. Ask what the person understands and what they want to know before delivering a plan. Re-open goals of care as a genuine question rather than a formality, since the calculus a patient applies to a second transplant is frequently different from the one they applied to the first. And name the option of disease-directed therapy alongside palliative support rather than presenting them as sequential alternatives, because integrating both is usually what serves the patient.
Who Relapses, and When
Relapse risk is not uniform, and knowing where a patient sits shapes the intensity of surveillance and the urgency of the response.
The dominant driver is disease biology and pre-transplant status: adverse-risk cytogenetics or molecular features, disease that was not in remission at transplant, and detectable measurable residual disease going into conditioning all carry substantially higher risk. Transplant variables contribute as well, including reduced-intensity conditioning in some settings, T-cell depletion, and the absence of graft-versus-host disease, since some graft-versus-malignancy effect travels with alloreactivity.
Timing follows a recognizable pattern. Most relapses after allogeneic transplantation occur within the first two years, with risk highest in the first year and declining thereafter, though late relapses do occur and are the reason surveillance does not simply stop at an anniversary. Patients frequently believe that passing the one-year mark means they are cured, and correcting that expectation gently - while not undermining legitimate reassurance - is part of survivorship teaching.
A patient is 8 months past allogeneic HCT for AML and remains on a tapering dose of tacrolimus with no GVHD. Routine surveillance shows CD3-selected donor chimerism falling from 98% to 82% over six weeks, with rising molecular measurable residual disease and a morphologically normal marrow. What response should the nurse anticipate the transplant team considering first?
A patient is scheduled to receive a donor lymphocyte infusion for early relapse after allogeneic HCT. Which pair of complications should the nurse prioritize in monitoring and patient teaching after the infusion?